According to the latest report, the global tissue microarray market size is predicted to reach USD 10,914.54 Million by the end of the year 2023 with a growth rate of 10.54% CAGR, during the forecast period. Tissue microarray is paraffin blocks where up to 1000 separate cylindrical tissue cores can be assembled in an array fashion which allows analyzing of molecules that are present n DNA, mRNA, and protein levels under similar standardized conditions on a single glass slide. This versatile strategy where data automated analysis provides prospective and retrospective human tissue studies.
The rising applications in discovery of drugs, the increasing advancements in pharmaceutical companies and biotechnology, rising generality of cancer, and increasing demand for accurate and cost-effective diagnostic methods are the major factor that is contributing to the growth of the global tissue microarray market. Array-based technology offers platforms for profiling of tissues such as DNA array and tissue array and disease genes; thousand of genres have been identified with the help of tissue microarray technology which can be associated with progression, initiation, and development. Moreover, tissue microarray is not beneficial for heterogeneous cancers and it is likely to create hurdles in the growth of the global tissue microarray market.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1213
Increasing application of tissue microarray in drug discovery and oncology, automated analysis of results, and influence of technology are some of the major factors that fosters the growth of the global tissue microarray market. Moreover, wide applications of tissue microarray in pathology is another factor, which is impelling the growth of tissue microarray market.
Major Players in the tissue microarray Market
Some of the key players in the global market are Agilent Technologies, Illumina, Inc., Protein Biotechnologies Inc., Asterand Bioscience, Pantomics Inc., Applied Microarrays, Arrayit, Phalanx Biotech, Qiagen, Takara Bio, Perkin Elmer, Merck Sharp Dohme Corp, and general electric and others.
The global tissue microarray market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East Africa.
The Americas is the leading market across the globe on account of constantly increasing cancer patient population, increasing number of cases in children, and increasing government support for research in healthcare domain and it is likely to flourish the Americas market over the review period.
Europe holds the second position in the market due to development in healthcare domain. During the last 30 years, in Europe biotechnology industry has developed gradually. Even though in Germany federal support programs started very early to target biotechnology, the innovative performance of this sector has been lagging behind that of the US, where the federal support was less direct earlier. Advances in technology in the healthcare sector have minimized human effort and increased the quality of patient care services, which will boost the market growth.
Asia Pacific is expected to be the fastest growing market owing to the concentration of emerging player and focus of established market leaders in this region. Moreover, the rising incidence of cancer in Asia Pacific has prompted suppliers and manufacturers to expand their market reach and to enter emerging markets. According to the Centers for Disease Control and Prevention (CDC), life-threatening or chronic diseases such as stroke, heart disease, cancer, diabetes, and chronic respiratory diseases, kidney diseases were the leading cause of death in 2014.
On the other hand, the Middle East Africa owns the minimum market share of the tissue microarray market due to less development in healthcare services such as new and advanced diagnosis treatment methods in healthcare domain.
The global tissue microarray market is segmented on the basis of procedure, technology, application, and end user.
On the basis procedure, it is segmented into immunohistochemistry, fluorescent in-situ hybridization, and frozen tissue array.
On the basis of technology, it is segmented into DNA microarray, polymerase chain reaction, next-generation sequencing, northern blotting, and western blotting.
On the basis of application, it is segmented in to oncology, gene expression profiling, SNP detection, double-stranded B-DNA microarrays, and comparative genomic hybridization, and sequencing bioinformatics.
On the basis of end user, it is segmented into pharmaceutical and biotechnological companies, research organization, and others.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/tissue-microarray-market-1213